Pluri (NASDAQ:PLUR) Trading Up 0.5% – Should You Buy?

Posted by Defense World Staff on Oct 25th, 2025

Pluri Inc. (NASDAQ:PLUR – Get Free Report) shares were up 0.5% on Friday . The company traded as high as $3.95 and last traded at $3.90. Approximately 7,611 shares were traded during trading, a decline of 27% from the average daily volume of 10,461 shares. The stock had previously closed at $3.88.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pluri in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $12.00.

Get Our Latest Stock Report on Pluri

Pluri Trading Up 0.5%

The company has a debt-to-equity ratio of 51.65, a quick ratio of 0.68 and a current ratio of 0.68. The company has a 50-day simple moving average of $4.67 and a 200 day simple moving average of $4.78. The company has a market capitalization of $31.82 million, a P/E ratio of -0.75 and a beta of 0.66.

Pluri (NASDAQ:PLUR – Get Free Report) last issued its quarterly earnings results on Wednesday, September 17th. The company reported ($2.62) EPS for the quarter, missing the consensus estimate of ($0.73) by ($1.89). The business had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.40 million. Pluri had a negative return on equity of 4,191.91% and a negative net margin of 1,701.19%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in Pluri Inc. (NASDAQ:PLUR – Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. Hedge funds and other institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

(Get Free Report)

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.